The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer. Issue 3 (8th October 2021)

• Record Type: Journal Article
• Authors: Boerrigter, Emmy; Benoist, Guillemette E.; Overbeek, Joanneke K.; Donders, Rogier; Mehra, Niven; van Oort, Inge M.; ter Heine, Rob; van Erp, Nielka P.
• Is Part Of: British journal of clinical pharmacology. Volume 88:Issue 3(2022)
• Page Start: 1170
• Page End: 1178
• Publication Date: 2021-10-08
• Subjects: abiraterone acetate -- castration‐resistant prostate cancer -- exposure–response -- pharmacokinetics -- survival; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.15057
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: To assess whether the exposure–response relation for abiraterone is different in pre‐chemotherapy patients compared to post‐chemotherapy patients with metastatic castration‐resistant prostate cancer (mCRPC). Methods: Data were collected from three clinical studies in mCRPC patients treated with abiraterone acetate. Cox regression analysis was used to determine the relation between abiraterone exposure and survival (progression‐free survival [PFS] and overall survival [OS]). An interaction term was used to test whether chemotherapy pretreatment was an effect modifier. To investigate the effect of the previously defined exposure threshold of 8.4 ng/mL on survival, Kaplan–Meier analysis was used. Results: In total, 98 mCRPC patients were included, of which 78 were pre‐chemotherapy and 20 were post‐chemotherapy patients. Chemotherapy pretreatment in mCRPC setting appears to be an effect modifier. In pre‐chemotherapy patients, no significant association between abiraterone exposure and survival was observed (HR 0.68 [95% CI 0.42–1.10], P = .12 and HR 0.85 [95% CI 0.46–1.60], P = .61, PFS and OS, respectively) and no longer survival was seen for patients with an abiraterone exposure above the predefined threshold. In contrast, a significant association was seen in post‐chemotherapy patients (HR 0.30 [95% CI 0.12–0.74], P = .01 and HR 0.38 [95% CI 0.18–0.82] P = .01, PFS and OS, respectively), with an increased survival when exposed above this threshold. Conclusion: Chemotherapy pretreatment in mCRPC setting modifies the abiraterone exposure–response relation. No relation between abiraterone exposure and survival was seen for pre‐chemotherapy patients. Therefore, potentially lower doses can be used in this setting to prevent overtreatment and reduce financial toxicity.